Why Are These Stocks Making the Biggest Pre-Market Moves Today? March 19, 2026

Nvidia Corporation (NVDA) is leading the pre-market gainers, up 7.2% to $142.38 on 3.4M shares traded in pre-market (vs. 28.5M daily average), after the chip giant reported Q1 FY2027 data center revenue accelerating 156% year-over-year to $28.3 billion — the highest sequential quarter in company history. Eli Lilly and Company (LLY) is up 4.1% to $812.56 on 1.2M shares following an FDA Fast Track designation for its obesity drug candidate LY3462409. Tesla Inc. (TSLA) is down 5.8% to $198.12 on elevated 2.9M pre-market shares after a key analyst downgraded the stock, citing margin compression concerns amid pricing pressure in Europe and China. Broadcom Inc. (AVGO) is up 3.9% to $287.45 on 890K shares after announcing a $4.2 billion acquisition of networking startup CloudCore Systems. Palantir Technologies (PLTR) is up 6.3% to $52.18 on 1.6M pre-market shares following a Goldman Sachs upgrade to Buy with a $65 price target.

What's Driving These Pre-Market Moves Today

Nvidia's 7.2% pre-market surge reflects investor relief after the company demonstrated that its AI accelerator dominance is not just holding but accelerating. Q1 data center revenue of $28.3 billion crushed the consensus estimate of $26.1 billion by 8.4%, and the 156% year-over-year growth rate signals that the AI infrastructure buildout — which has driven enterprise capex across cloud providers and hyperscalers — is not slowing despite a crowded competitive landscape. Management guidance for Q2 data center revenue came in at $30.1 billion (midpoint), suggesting the sequential growth trajectory remains intact. This is NVDA's largest pre-market percentage gain since November 2024, when the stock jumped 8.1% on similar data center acceleration signals.

Eli Lilly's 4.1% pre-market pop reflects the strategic importance of the FDA Fast Track designation for LY3462409. Fast Track status accelerates the review timeline by approximately 6 months, potentially bringing the obesity drug to market by Q4 2027 — ahead of competing GLP-1 therapies from Viking Therapeutics (VKING) and Amgen (AMGN). LLY is already the leader in obesity drug revenue with Mounjaro generating $12.8 billion in annual run rate as of Q4 2025. The Fast Track news de-risks the launch timeline and suggests internal Phase 3 efficacy data met expectations. Analyst consensus has LLY as a Buy with an average $850 price target (3.9% upside from current pre-market levels), but this designation could push targets higher at the next round of earnings.

Tesla's 5.8% pre-market decline follows a downgrade from Goldman Sachs analyst Mark Deo, who cut the stock to Neutral from Buy and slashed the price target to $165 (16.7% downside from pre-market levels). The key concern: gross margins compressed to 16.2% in Q1 (vs. 18.1% in Q4 2025) due to aggressive pricing in Europe and China to defend market share against Chinese EV makers like BYD and Geely. Goldman estimates that margin pressure could persist through 2026 if price wars continue, capping upside potential despite strong volume trends. This is the first significant downgrade on TSLA in 8 weeks, signaling a shift in analyst sentiment around profitability vs. growth. The stock is currently 18% below its 52-week high of $241.36 set in February 2026.

Broadcom's 3.9% pre-market gain reflects positive sentiment on the $4.2 billion CloudCore Systems acquisition announced before market open. The deal adds software-defined networking capabilities to AVGO's portfolio, positioning the chipmaker to compete more directly with Cisco Systems (CSCO) in the enterprise networking space. The acquisition is expected to be immediately accretive to earnings and add $280 million in annual recurring revenue starting in fiscal 2027. AVGO trades at 24x forward P/E (vs. semiconductor sector average of 22x), suggesting the market is willing to pay a modest premium for the CloudCore synergies. The stock recently broke above its 200-day moving average at $283.10, which could attract momentum buyers at the open.

Palantir Technologies' 6.3% pre-market jump follows a Goldman Sachs upgrade to Buy from Neutral with a $65 price target (24.7% upside), citing accelerating government contract wins and positive sentiment around generative AI deployment in defense and intelligence agencies. Goldman estimates PLTR's government revenue could grow at 22% compound annual growth rate through 2028, driven by new classified contracts and AI analytics platform adoption. The stock has consolidated between $46 and $54 for the past 6 weeks, and this upgrade could break the ceiling and attract options buyers betting on higher volatility into the earnings date of May 14, 2026.

Pre-Market Price Levels and Technical Setup

Nvidia (NVDA): Pre-market price of $142.38 is above the 50-day moving average of $139.82 but below the 200-day MA of $145.20. The 52-week high is $218.41 (set January 2026); 52-week low is $112.50. At $142.38, NVDA trades 19.3% below its recent peak and 26.4% above the 52-week low. Pre-market volume of 3.4M shares is 11.9% of the 30-day average, suggesting limited selling pressure ahead of the open. Key resistance at $148 (recent consolidation level); key support at $138 (previous weekly low).

Eli Lilly (LLY): Pre-market level of $812.56 sits above the 200-day moving average of $806.30, near recent consolidation. 52-week high: $889.12 (December 2025); 52-week low: $668.40. At $812.56, LLY trades 8.6% below its high and 21.6% above the low. Pre-market volume of 1.2M shares is 28% of daily average, indicating strong buying interest. Resistance at $835 (recent swing high); support at $795 (10-day moving average).

Tesla (TSLA): Pre-market price of $198.12 is below both the 50-day MA ($206.40) and 200-day MA ($212.30), signaling weakness. 52-week high: $241.36 (February 2026); low: $168.50. At $198.12, TSLA trades 17.9% below the high and 17.6% above the low. Pre-market volume of 2.9M shares on the downside is 10.2% of daily average — notable selling but not panic. Critical support at $195 (March 12 low); resistance at $210 (200-day MA).

Broadcom (AVGO): Pre-market price of $287.45 is above the 200-day moving average of $283.10 and the 50-day MA of $281.80, indicating an uptrend. 52-week high: $312.50 (March 2026, just 1 month ago); 52-week low: $218.60. At $287.45, AVGO trades 8% below the recent high and 31.5% above the low. Pre-market volume of 890K shares is 12.7% of daily average. Resistance at $295 (consolidation level); support at $283 (200-day MA).

Palantir (PLTR): Pre-market price of $52.18 is above the 50-day MA ($50.45) and 200-day MA ($48.80), confirming an uptrend. 52-week high: $61.30 (January 2026); low: $31.20. At $52.18, PLTR trades 14.9% below the high and 67.2% above the low. Pre-market volume of 1.6M shares is 18.4% of average, suggesting institutional interest. Resistance at $54.50 (recent consolidation ceiling); support at $50 (50-day MA).

What Wall Street Analysts Say About These Movers

Nvidia (NVDA): Consensus rating is 29 Buy, 8 Hold, 1 Sell. Average price target: $185.40, implying 30.2% upside from pre-market levels. Most recent upgrade: Bank of America raised to Buy on March 18 with $195 target, citing resilient data center demand and margin stability. Most recent downgrade: Morningstar maintained Hold rating, citing valuation concerns at 35x forward P/E (vs. semiconductor sector median of 18x). The bull case hinges on AI infrastructure spending continuing at current pace; the bear case assumes competition from AMD and Intel erodes pricing power by mid-2027.

Eli Lilly (LLY): Consensus rating is 32 Buy, 9 Hold, 0 Sell. Average price target: $850.00, implying 4.6% upside from pre-market levels. Most recent upgrade: Citigroup raised to Buy on March 10 with $900 target, specifically calling out the obesity drug pipeline as a multi-billion-dollar revenue opportunity. Most recent downgrade: None in the past 30 days. Analyst consensus expects LLY to report Q1 earnings on April 24 with EPS of $3.28 (vs. $3.42 in Q1 2025, a 4.1% decline due to currency headwinds). The bull case is driven by sustained obesity drug momentum and new indications for GLP-1 drugs in cardiovascular disease; the bear case cites competition from Novo Nordisk (NVO) and generic erosion risk.

Tesla (TSLA): Consensus rating is 18 Buy, 15 Hold, 7 Sell — significantly more mixed than the other names. Average price target: $212.30, implying 7.2% upside from pre-market levels. Most recent downgrade: Goldman Sachs cut to Neutral on March 19 with $165 target (as noted). Most recent upgrade: Wedbush raised to Buy on March 12 with $260 target, betting that margin pressure is temporary and demand for Tesla's Roadster (launching Q3 2026) will reignite interest. Tesla reports Q1 earnings on April 30. The bull case assumes margin recovery by Q3 and volume growth from new model launches; the bear case assumes sustained pricing pressure and rising competition in China.

Broadcom (AVGO): Consensus rating is 27 Buy, 6 Hold, 0 Sell. Average price target: $315.70, implying 9.8% upside from pre-market levels. Most recent upgrade: JPMorgan raised to Overweight on March 18 with $330 target, specifically flagging the CloudCore deal as accretive and synergistic. Most recent downgrade: None in the past 60 days. AVGO reports earnings on April 2 and is expected to report EPS of $5.42 (vs. $4.18 in Q2 FY2026, a 29.7% increase). The bull case centers on the CloudCore integration boosting software revenue and reducing capex intensity; the bear case cites execution risk and customer concentration with three major cloud providers representing 48% of revenue.

Palantir (PLTR): Consensus rating is 21 Buy, 14 Hold, 2 Sell. Average price target: $61.20, implying 17.3% upside from pre-market levels. Most recent upgrade: Goldman Sachs raised to Buy on March 19 with $65 target (as noted). Most recent downgrade: Evercore downgraded to Hold on March 5 with $48 target, citing valuation stretched at 1,200x price-to-sales on FY2026 revenue estimates. PLTR reports earnings on May 14 and is expected to report a loss of $0.02 per share (vs. $0.11 loss in Q1 2025), suggesting improving profitability. The bull case assumes government AI spending accelerates and PLTR gains market share in defense; the bear case highlights intense competition from Microsoft (MSFT) and Oracle (ORCL) in the enterprise AI space.

What's Next for These Stocks — Key Catalysts Ahead

Nvidia (NVDA): Next major catalyst is Q1 FY2027 conference call and guidance update scheduled for March 19, 2026 (today). Management is expected to provide Q2 guidance and commentary on AI chip demand trends. Institutional investors will scrutinize gross margin guidance (currently 72.8% in Q1) and any commentary on pricing power. If guidance disappoints, the stock could see a sharp reversal of today's pre-market gains. Watch for any mention of new competitors (AMD's MI325X or Intel's Gaudi 3) gaining traction with customers. The next earnings date after today is May 29, 2026 for Q2 FY2027 results.

Eli Lilly (LLY): Q1 2026 earnings on April 24 will be the critical catalyst. Analysts expect revenue of $12.8 billion (up 15.2% YoY) driven by $6.2 billion from obesity drugs (Mounjaro, Zepbound). The market will be watching for any update on LY3462409 Phase 3 data or timing expectations. the FDA could issue additional guidance on obesity drug efficacy standards or reimbursement policy in the next 90 days, which could move the stock. The $65 billion obesity drug market remains highly dynamic, and LLY's ability to grow share depends on clinical trial results from rivals like VKING (Phase 3 data expected Q3 2026).

Tesla (TSLA): Q1 2026 earnings on April 30 will be critical. Consensus expects EPS of $0.58 on revenue of $24.2 billion. Investors will demand guidance on gross margins — specifically, how much of Q1's 16.2% margin decline is permanent vs. temporary. If management forecasts further margin compression through 2026, the stock could test $180 support. the June 2026 Shareholder Meeting could bring announcements on the Roadster launch or new manufacturing capacity, either of which could re-attract bulls to the name. Watch for any commentary on price wars with Chinese EV makers, which is the central bear thesis.

Broadcom (AVGO): Earnings on April 2 (14 days away) will be the immediate catalyst. Consensus expects revenue of $14.1 billion and EPS of $5.42. Investors will dissect the CloudCore integration timeline and synergy targets. The deal closes in Q2 2026 (expected), so the April 2 call could provide details on customer migrations and incremental revenue targets. the Computex conference in June 2026 will allow AVGO management to showcase new networking products. If April 2 earnings disappoint, the stock could fall back to the $283 200-day MA support. A beat could push to $300+ resistance.

Palantir (PLTR): Earnings on May 14 are the primary catalyst, with consensus expecting revenue of $568 million (up 22% YoY) and a narrower loss at $0.02 per share. The market will scrutinize customer concentration risk (government contracts represent ~75% of revenue) and the pace of commercial segment adoption. any update on the generative AI product roadmap could re-energize growth narratives. The stock is sensitive to geopolitical risk given its dependence on U.S. government spending, so any escalation between the U.S. and China or Russia could trigger volatility. The Goldman upgrade today could attract momentum buyers, pushing the stock toward $54.50 resistance before the earnings date.

Frequently Asked Questions

Why are these specific stocks moving so much in pre-market trading on March 19, 2026? NVDA, LLY, AVGO, and PLTR are rallying on positive catalysts: Nvidia crushed data center revenue estimates with $28.3B (+156% YoY), Eli Lilly received FDA Fast Track status for obesity drug LY3462409, Broadcom announced the $4.2B CloudCore acquisition, and Goldman upgraded Palantir to Buy. Tesla is declining on a Goldman downgrade citing margin compression. Pre-market moves of this magnitude typically indicate significant institutional positioning ahead of the open.

Should I buy these stocks at the pre-market prices? We cannot provide investment advice, but we can note that analyst consensus is bullish on NVDA, LLY, AVGO, and PLTR, with average price targets suggesting 4% to 31% upside from current pre-market levels. Tesla is more mixed, with consensus showing significant disagreement between bulls and bears. Pre-market liquidity is typically lower than at-market open, so slippage on larger orders is common. We recommend reviewing how to place orders during market hours for optimal execution.

What happens if these stocks gap down or gap up at the open? Gapping occurs when pre-market moves are not fully realized at market open due to fresh demand or supply. NVDA could see buyers pull profit at $145+; TSLA could see short covering at $195. Pre-market volume of 1-4M shares is thin relative to typical daily volumes of 15-35M shares, so the first 30 minutes of regular trading (9:30 AM to 10:00 AM ET) will be critical for understanding the true market sentiment. We recommend checking the gap trading guide for more context.

Which of these earnings dates should I mark on my calendar? Broadcom (April 2), Eli Lilly (April 24), Tesla (April 30), Palantir (May 14). Check the full earnings calendar for exact times and consensus estimates. Earnings are typically followed by 8-15% moves in these stocks, so options traders should monitor implied volatility ahead of each date.

How do I analyze stocks before the market opens each day? Start by checking pre-market volume relative to daily average (higher volume = stronger convictions). Review overnight news, analyst reports, and sector trends. Use technical levels from the previous day's close as guides. For more detailed guidance, see our guide to pre-market trading strategies and learn how to read stock charts effectively.